TP53 and medulloblastoma: We also enforced expression of a TP53 dominant negative mutant (dn-p53) in the medulloblastoma cell line most responsive to RITA treatment (HD-MB03) and the ONS-76 cell line, which was less sensitive to RITA treatment (Supplementary Figure 1).